Abstract
Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-levels of Gem Vin, administered on days 1 and 8 every 3 weeks, were (mg m–2): level I = 1000/25; level II = 1200/25; level III = 1000/30; level IV = 1200/30. A feasibility study was performed at each dose-level, followed by a single-stage phase II study. Dose-level IV was unfeasible because of grade 4 neutropenia. Overall, out of 126 patients enrolled in phase II studies, there were one complete and 32 partial responses (response rate 26%: 95% CI 18–34%). Response rates were 27.9%, 21.4% and 29.3% at levels I, II and III, respectively. The treatment was well tolerated. Toxicity was less frequent and severe at level I. Overall median survival was 33 weeks (95% CI 28–40). Descriptive quality of life analysis showed that patients with a worse baseline global health status score tended to drop out of the study earlier than those with a better score. Gem Vin is feasible at different doses. It is sufficiently active and well tolerated. A phase III study to compare the effect on quality of life of Gem Vin (level I) vs cisplatin-based chemotherapy is ongoing. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Fletchner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M and Takeda F for the EORTC Study Group on Quality of Life (1993) The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Albein KS, Crowley II, LeBlanc M and Livingston B (1991) Survival determinants in extensive disease non small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626
Bergman B, Aaronson NK, Ahmedzai S, Kaasa S and Sullivan M for the EORTC Study Group on Quality of Life (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A: 635–642
Chen YM, Whang-Peng J, Perng RP, Liu TW, Yang KY, Lin WC, Wu HW, Shih JF, Liu JM, Chen LT and Tsai CM (1999) A multicenter phase II study of gemcitabine and vinorelbine in patients with advanced stage IIIB-IV non small cell lung cancer. Proc Am Soc Clin Oncol 18: 481a, 1856
Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Hilleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Jolal-Celigny P, Badri N and Besenval M (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial. Ann Oncol 5: 37–42
Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66–72
Feliu J, Lopez Gomez L, Madronal C, Espinosa E, Espinosa J, Garcia Giron C, Martinez B, Castro J, De la Gandara I and Baron MG for the Oncopaz Cooperative Group (1999) Gemcitabine plus vinorelbine in non small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 86: 1463–1469
Gatzmeier U, Heckmayr M, Hossfeld DK, Kaukel E, Koschel G and Neuhauss R (1991) A randomized trial of mitomycin C/ifosfamide vs mitomycin C/vindesine, vs cisplatin/etoposide in advanced non small cell lung cancer. Am J Clin Oncol 14: 405–411
Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardalis N and Vlachonicoli J (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17: 914–920
Gridelli C, Perrone F, Palmeri S, D’Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S and Bianco AR (1996) Mitomycin C plus vindesine plus etoposide (MEV) versus mytomicin C plus vindesine plus cisplatin (MVP) in stage IV non small cell lung cancer: a phase III multicenter randomised trial. Ann Oncol 7: 821–826
Kaplan EL and Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457–481
Kourousis C, Androulakis N, Kakalyris S, Souglakos J, Maltezakis G, Metaxaris G, Chalkiadakis G, Samonis G, Vlachonikolis J and Georgoulias V (1998) First-line treatment of advanced non small cell lung carcinoma with docetaxel and vinorelbine. Cancer 83: 2083–2090
Isokangas OP, Knuuttila A, Halme M, Mäntylä M, Lindström I, Nikkanen V, Viren M, Joensuu H and Mattson K (1999) Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 10: 1059–1063
LeChevalier T, Brisgand D, Douillard JY, Pusol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P and Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360–367
Luedke DW, Einhorn J, Omura GA, Ravisarma P, Bartolucci AA, Birch R and Greco FA (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in non small cell lung cancer. A Southern Cancer Study Group Trial. J Clin Oncol 8: 886–891
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, von Walree N and ten Bokkel-Huinink W (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8: 525–529
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Non Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311: 899–909
Pern RP, Chen YM, Ming-Liu J, Tsai C-M, Lin WC, Yang KY and Whang-Peng J (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15: 2097–2102
Ruckdeshel JC, Gridelli C, Perrone F, Monfardini S and Giaccone G (1998) Are platinum compounds mandatory in the treatment of metastatic non small cell lung cancer?. Eur J Cancer 13: 1993–1999
Sandler A, Nemunaitis J, Denham C, Cormier Y, von Pawel J, Niyikiza C, Nguyen B and Einhorn L (1998) Phase III study of cisplatin with or without gemcitabine in patients with advanced non small cell lung cancer. Proc Am Soc Clin Oncol 17: 454a–1747
Shinkai T, Sajio N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J and Futami H (1985) Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non small cell lung cancer. Cancer Treat Rep 69: 945–951
Simon R, Wittes RE and Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375–1381
Author information
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gridelli, C., Frontini, L., Perrone, F. et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Br J Cancer 83, 707–714 (2000). https://doi.org/10.1054/bjoc.2000.1341
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1341
Keywords
This article is cited by
-
Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphoma
Medical Oncology (2013)
-
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
British Journal of Cancer (2012)
-
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
Investigational New Drugs (2008)
-
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Cancer Chemotherapy and Pharmacology (2007)
-
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
British Journal of Cancer (2003)